HCPCS Level II · April 2026
New HCPCS Level II Codes for April 2026
Effective . 62 new codes in this release.
← All changes in April 2026| Code | Description |
|---|---|
| A2040 | Microlyte painguard, per square centimeter |
| A2041 | Foundation drs+ duo, per square centimeter |
| A2042 | Foundation drs+ solo, per square centimeter |
| A2043 | Biobrane, per square centimeter |
| A2044 | Biobrane glove, each |
| A2045 | Novashield or novogen wound matrix, per square centimeter |
| A4318 | Female external urinary collection cup, with or without ring attachment, per day |
| A4479 | Electronic transanal irrigation system, includes electronic pump, water reservoir, tubing, and accessories, without catheter, any type |
| A6548 | Accessory to custom gradient compression garment, silicone band, any size |
| A8005 | Powered, cable driven grip assist glove, hand, finger, includes microprocessor, pressure sensors, all components and accessories, custom fitted |
| A8006 | Powered, cable driven grip assist glove, hand, finger, includes pressure sensors, glove replacement only |
| A9294 | Prescription digital cognitive and/or behavioral therapy, biofeedback, fda cleared, per course of treatment |
| C1743 | Scaffold, endovascular non-coronary, resorbable drug eluting, with delivery system (implantable) |
| C8007 | Open implantation of hypoglossal nerve neurostimulator array and pulse generator, not requiring insertion of a separate distal respiratory sensor electrode or electrode array |
| C8008 | Revision or replacement of hypoglossal nerve neurostimulator array including connection to existing pulse generator |
| C8009 | Removal of hypoglossal nerve neurostimulator array and pulse generator |
| C8010 | Percutaneous placement of permanent common carotid embolic protection device, including all system components and imaging guidance; bilateral |
| C8011 | Open implantation of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver, including external power source and all system components |
| C8012 | Revision or replacement of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver |
| C8013 | Removal of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver |
| C9309 | Injection, onasemnogene abeparvovec-brve, per treatment |
| C9818 | Suzetrigine, oral, 1 mg |
| G0680 | Detection and quantification of coronary artery calcium and/or aortic valve calcification from algorithmic analysis of computed tomography of the chest with report |
| G0681 | Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less of wound surface area |
| G0682 | Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure) |
| G0683 | Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children |
| G0684 | Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure) |
| J0463 | Injection, atropine sulfate (fresenius and therapeutically equivalent), 0.01 mg |
| J1098 | Articaine ophthalmic, 8% solution, 0.4 ml |
| J1164 | Injection, diltiazem hydrochloride in 0.72% sodium chloride, 0.5 mg |
| J1553 | Injection, immune globulin (yimmugo), 100 mg |
| J3404 | Injection, zopapogene imadenovec-drba suspension, per therapeutic dose |
| J8502 | Injection, aprepitant (aponvie), 1 mg |
| J9003 | Leuprolide injectable (camcevi etm), 1 mg |
| J9183 | Gemcitabine intravesical system, 225 mg |
| J9277 | Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph |
| J9278 | Injection, carboplatin (avyxa), 1 mg |
| J9601 | Injection, linvoseltamab-gcpt, 1 mg |
| L2221 | Addition to lower extremity orthosis, ankle system, microprocessor-controlled feature plantarflexion and/or dorsiflexion, includes power source |
| L5992 | All lower extremity prosthesis, foot shell for modular foot/non-solid ankle cushion heel (sach) replacement only |
| M0233 | Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose |
| M0234 | Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose |
| Q0238 | Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg |
| Q4418 | Biolab membrane wrap flow, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4419 | Biolab membrane wrap lite flow, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4421 | Biolab membrane wrap solo, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4422 | A/c wrap, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4423 | Biolab tri-membrane wrap flow, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4424 | Revive ft, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4425 | Revive tl, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4426 | Dermabind tl + or dermabind tl x, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4427 | Dermabind dl n or dermabind dl + or dermabind dl x, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4428 | Dermabind sl n or dermabind sl + or dermabind sl x, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4429 | Dermabind ch n or dermabind ch x, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4435 | Renati membrane, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4436 | Renati ac membrane, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4437 | Revival ac, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4438 | Pretect, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4439 | Instagraft, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q4440 | Curamatrix, per square centimeter (add-on, list separately in addition to primary procedure) |
| Q5161 | Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg |